ID: ALA400491

Max Phase: Preclinical

Molecular Formula: C23H31N7O2

Molecular Weight: 437.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCN1CCC2(CC1)NC(=O)N(Cc1cc3cnc(C#N)nc3n1CC(C)(C)C)C2=O

Standard InChI:  InChI=1S/C23H31N7O2/c1-5-8-28-9-6-23(7-10-28)20(31)29(21(32)27-23)14-17-11-16-13-25-18(12-24)26-19(16)30(17)15-22(2,3)4/h11,13H,5-10,14-15H2,1-4H3,(H,27,32)

Standard InChI Key:  DRKAFUGFRPVJKV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 437.55

Molecular Weight (Monoisotopic): 437.2539

AlogP: 2.65

#Rotatable Bonds: 5

Polar Surface Area: 107.15

Molecular Species: BASE

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.26

CX Basic pKa: 9.04

CX LogP: 2.45

CX LogD: 0.80

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.72

Np Likeness Score: -1.33

References

1. Teno N, Miyake T, Ehara T, Irie O, Sakaki J, Ohmori O, Gunji H, Matsuura N, Masuya K, Hitomi Y, Nonomura K, Horiuchi M, Gohda K, Iwasaki A, Umemura I, Tada S, Kometani M, Iwasaki G, Cowan-Jacob SW, Missbach M, Lattmann R, Betschart C..  (2007)  Novel scaffold for cathepsin K inhibitors.,  17  (22): [PMID:17911019] [10.1016/j.bmcl.2007.09.047]

2. Teno N, Masuya K, Ehara T, Kosaka T, Miyake T, Irie O, Hitomi Y, Matsuura N, Umemura I, Iwasaki G, Fukaya H, Toriyama K, Uchiyama N, Nonomura K, Sugiyama I, Kometani M..  (2008)  Effect of cathepsin K inhibitors on bone resorption.,  51  (17): [PMID:18707091] [10.1021/jm800626a]

Source

Source(1):

• Scientific Literature